SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. Financials Shenzhen Kangtai Biological Products Co., Ltd.
Equities
300601
CNE100002Q33
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.75 CNY | +7.01% |
|
+4.06% | -23.57% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 22,769 | 56,644 | 119,407 | 67,700 | 27,232 | 23,176 | 23,176 | - |
| Enterprise Value (EV) 1 | 22,769 | 56,644 | 119,407 | 66,889 | 28,504 | 31,593 | 23,233 | 22,803 |
| P/E ratio | 51.1 x | 97.5 x | 173 x | 54.1 x | -263 x | 35.3 x | 16.8 x | 12.8 x |
| Yield | - | - | - | 0.86% | - | 0.74% | 2.06% | 2.49% |
| Capitalization / Revenue | 11.3 x | 29.1 x | 52.8 x | 18.5 x | 8.62 x | 8.72 x | 4.82 x | 3.92 x |
| EV / Revenue | 11.3 x | 29.1 x | 52.8 x | 18.3 x | 9.03 x | 9.09 x | 4.83 x | 3.86 x |
| EV / EBITDA | - | 76.3 x | 135 x | 35.5 x | -322 x | 26.6 x | 12.1 x | 9.6 x |
| EV / FCF | - | 475 x | - | -75.3 x | -37.3 x | 100 x | 32.9 x | 19.6 x |
| FCF Yield | - | 0.21% | - | -1.33% | -2.68% | 1% | 3.04% | 5.09% |
| Price to Book | 12.5 x | 20.6 x | 16 x | 7.82 x | 4.17 x | 3.36 x | 2.08 x | 1.78 x |
| Nbr of stocks (in thousands) | 1,018,160 | 1,032,353 | 1,094,851 | 1,099,252 | 863,699 | 1,116,917 | 1,116,917 | - |
| Reference price 2 | 22.36 | 54.87 | 109.1 | 61.59 | 31.53 | 20.75 | 20.75 | 20.75 |
| Announcement Date | 2/26/19 | 2/28/20 | 4/29/21 | 4/13/22 | 4/23/23 | 4/26/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,017 | 1,943 | 2,261 | 3,652 | 3,157 | 3,477 | 4,809 | 5,912 |
| EBITDA 1 | - | 742.1 | 881.9 | 1,885 | -88.53 | 1,190 | 1,927 | 2,376 |
| EBIT 1 | 481.3 | 657.8 | 775.4 | 1,452 | -317.6 | 948.9 | 1,571 | 2,061 |
| Operating Margin | 23.86% | 33.85% | 34.29% | 39.76% | -10.06% | 27.29% | 32.66% | 34.87% |
| Earnings before Tax (EBT) 1 | 489.1 | 663.4 | 772.4 | 1,439 | -338.2 | 940.3 | 1,572 | 2,067 |
| Net income 1 | 435.7 | 574.5 | 679.2 | 1,263 | -132.7 | 861.3 | 1,343 | 1,750 |
| Net margin | 21.6% | 29.56% | 30.04% | 34.59% | -4.2% | 24.77% | 27.92% | 29.6% |
| EPS 2 | 0.4375 | 0.5625 | 0.6312 | 1.138 | -0.1200 | 0.7700 | 1.238 | 1.623 |
| Free Cash Flow 1 | - | 119.3 | - | -888 | -764.6 | 315.6 | 707 | 1,161 |
| FCF margin | - | 6.14% | - | -24.31% | -24.22% | 9.08% | 14.7% | 19.64% |
| FCF Conversion (EBITDA) | - | 16.08% | - | - | - | 26.53% | 36.68% | 48.86% |
| FCF Conversion (Net income) | - | 20.77% | - | - | - | 36.64% | 52.65% | 66.34% |
| Dividend per Share 2 | - | - | - | 0.5312 | - | 0.2000 | 0.4275 | 0.5175 |
| Announcement Date | 2/26/19 | 2/28/20 | 4/29/21 | 4/13/22 | 4/23/23 | 4/26/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,325 | 1,275 | 871.4 | 956.4 | 737.2 | 592.3 | 748.4 | 982.2 | 733.9 | 1,013 | 887.4 | 1,058 | 1,186 | 1,338 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 808.7 | 255.8 | 327.2 | -239 | 64.69 | -470.2 | 244.3 | 322 | 202.4 | 180.2 | 276 | 337.3 | 390.3 | - |
| Operating Margin | - | 61.03% | 20.07% | 37.55% | -24.98% | 8.77% | -79.37% | 32.65% | 32.78% | 27.58% | 17.79% | 31.1% | 31.89% | 32.9% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | -153.1 | 82.64 | -335.9 | - | 305 | 186.6 | - | - | - | - | - |
| Net margin | - | - | - | - | -16.01% | 11.21% | -56.7% | - | 31.05% | 25.43% | - | - | - | - | - |
| EPS | 0.2813 | 0.6252 | 0.2062 | - | -0.2236 | 0.0693 | -0.3600 | - | 0.2763 | 0.1600 | - | - | - | - | - |
| Dividend per Share | 0.1875 | - | 0.0531 | - | - | - | - | - | 0.1800 | - | - | - | - | - | - |
| Announcement Date | 8/30/21 | 10/22/21 | 4/13/22 | 4/27/22 | 8/18/22 | 10/27/22 | 4/23/23 | 4/23/23 | 8/26/23 | 10/26/23 | 4/26/24 | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1,272 | 1,269 | 57.3 | - |
| Net Cash position 1 | - | - | - | 811 | - | - | - | 373 |
| Leverage (Debt/EBITDA) | - | - | - | - | -14.37 x | 1.067 x | 0.0297 x | - |
| Free Cash Flow 1 | - | 119 | - | -888 | -765 | 316 | 707 | 1,161 |
| ROE (net income / shareholders' equity) | 30.9% | 25.5% | 12.6% | 15.1% | -1.44% | 9.26% | 12.1% | 13.4% |
| ROA (Net income/ Total Assets) | - | 15.8% | - | 9.04% | - | 7.35% | 8.08% | 8.95% |
| Assets 1 | - | 3,644 | - | 13,970 | - | 13,952 | 16,629 | 19,554 |
| Book Value Per Share 2 | 1.790 | 2.670 | 6.810 | 7.870 | 7.560 | 8.090 | 9.980 | 11.70 |
| Cash Flow per Share 2 | 0.3400 | 0.4900 | 0.4000 | 1.500 | 0.4900 | 0.9300 | 0.7600 | 1.160 |
| Capex 1 | - | 386 | 1,226 | 2,540 | 1,310 | 717 | 726 | 634 |
| Capex / Sales | - | 19.88% | 54.2% | 69.56% | 41.5% | 20.63% | 15.1% | 10.73% |
| Announcement Date | 2/26/19 | 2/28/20 | 4/29/21 | 4/13/22 | 4/23/23 | 4/26/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
20.75
CNY
Average target price
37.75
CNY
Spread / Average Target
+81.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.57% | 3.2B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 300601 Stock
- Financials Shenzhen Kangtai Biological Products Co., Ltd.
